Skip to main content

Proteomics International Licenses PromarkerD Test to Patia

NEW YORK (360Dx) – Australian proteomics firm Proteomics International Laboratories said today it has licensed its PromarkerD test for diabetic kidney disease to Patia BioPharma for commercialization in Mexico.

According to Proteomics International, Patia will develop and commercialize PromarkerD as a mass spec-based laboratory-developed test performed by its partner, Clinica Ruiz Laboratories.

It added that Patia plans to roll the test out in private hospitals and clinics first and then expand to government facilities and facilities run by the philanthropic Carlos Slim Foundation. The company said the first sales of the test are expected in the next four to six months.

"PromarkerD is a breakthrough test that allows us to preempt diabetic kidney disease, one of the most costly complications of diabetes," Laureano Simon, CEO of Patia, said in a statement. "This predictive test will let us intervene early and prescribe treatments to prevent the disease, and help reverse the growing impact of diabetes on public health in Mexico."

According to Proteomics International, diabetes is the second leading cause of death in Mexico, and roughly 13 million adults in the country have the condition.

Proteomics International launched PromarkerD in the Dominican Republic in March 2018 and announced a US licensing deal for the test last month. It now aims to commercialize the test in countries including Japan, Australia, China, and various European countries.